Betterware de Mexico SAPI de C (NYSE:BWMX) and Niagen Bioscience (NASDAQ:NAGE) Critical Comparison

Niagen Bioscience (NASDAQ:NAGE) and Betterware de Mexico SAPI de C (NYSE:BWMX) are both small-cap consumer staples companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, analyst recommendations, valuation, profitability, institutional ownership, risk and earnings.

Valuation and Earnings

This table compares Niagen Bioscience and Betterware de Mexico SAPI de C”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Niagen Bioscience	$129.42 million	1.28	$17.38 million	$0.12	17.46
Betterware de Mexico SAPI de C	$16.31 billion	0.04	$55.37 million	$1.95	8.65

Betterware de Mexico SAPI de C has higher revenue and earnings than Niagen Bioscience. Betterware de Mexico SAPI de C is trading at a lower price-to-earnings ratio than Niagen Bioscience, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current ratings for Niagen Bioscience and Betterware de Mexico SAPI de C, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Niagen Bioscience	0	1	4	1	3.00
Betterware de Mexico SAPI de C	1	0	1	1	2.67

Niagen Bioscience presently has a consensus target price of $8.50, indicating a potential upside of 305.73%. Given Niagen Bioscience’s stronger consensus rating and higher probable upside, equities analysts clearly believe Niagen Bioscience is more favorable than Betterware de Mexico SAPI de C.

Risk and Volatility

Niagen Bioscience has a beta of 2.12, meaning that its share price is 112% more volatile than the S&P 500. Comparatively, Betterware de Mexico SAPI de C has a beta of 1.13, meaning that its share price is 13% more volatile than the S&P 500.

Insider & Institutional Ownership

15.4% of Niagen Bioscience shares are held by institutional investors. Comparatively, 12.7% of Betterware de Mexico SAPI de C shares are held by institutional investors. 10.0% of Niagen Bioscience shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Niagen Bioscience and Betterware de Mexico SAPI de C’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Niagen Bioscience	8.37%	10.18%	7.57%
Betterware de Mexico SAPI de C	8.08%	70.20%	10.82%

Summary

Niagen Bioscience beats Betterware de Mexico SAPI de C on 9 of the 14 factors compared between the two stocks.

About Niagen Bioscience

Niagen Bioscience, Inc. develops and markets products based on nicotinamide riboside (NR), a form of vitamin B3 studied for its role in supporting the body’s production of NAD+. Its offerings include Tru Niagen, a consumer dietary supplement, and Niagen, a branded NR ingredient supplied to other businesses. The company also conducts and supports research on NR, NAD+ and healthy aging. It was formerly known as ChromaDex Corporation and adopted the Niagen Bioscience name in 2025. Niagen Bioscience serves consumers and commercial customers in the United States and international markets through online sales, retail and distribution channels.

About Betterware de Mexico SAPI de C

Betterware de México, S.A.P.I. de C.V. is a consumer products company that sells household and personal-care products through a direct-selling network. Its Betterware brand focuses on practical products for home organization, storage, kitchen use, cleaning and other everyday needs, which are marketed through independent distributors and company sales channels. The company’s Mexican operations date to 1995. In 2022, Betterware acquired JAFRA, adding a beauty and personal-care business whose products include cosmetics, fragrances and skin-care items, sold through a network of consultants.